Guidance for reading FDG PET scans in dementia patients.
18F-2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) is a powerful method for detection of disease-related impairment of cerebral glucose metabolism in neurodegenerative diseases. It is of particular interest for early and differential diagnosis of dementia. Reading FDG PET scans requires training to recognise deviations from normal functional brain anatomy and its variations. This paper provides guidance for displaying FDG PET brain scans in a reproducible manner that allows reliable recognition of characteristic disease-related metabolic changes. It also describes typical findings in Alzheimer's disease, Frontotemporal Dementia and Dementia with Lewy Bodies and possible confounding factors, such as vascular changes and brain atrophy. It provides a brief overview on findings in other neurodegenerative diseases and addresses the potential and limitations of software packages for comparison of individual scans with reference data.
Wolfson Molecular Imaging Centre and Manchester Academic Health Science Centre, University of Manchester, Manchester, UK - karl.herholz@manchester.ac.uk.
K
K
Herholz
D000544:Alzheimer Disease / Q000000981:diagnostic imaging; D001921:Brain / Q000000981:diagnostic imaging / Q000473:pathology; D003704:Dementia / Q000175:diagnosis* / Q000000981:diagnostic imaging*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007091:Image Processing, Computer-Assisted / Q000379:methods; D009683:Nuclear Medicine / Q000379:methods; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D012016:Reference Values; D012984:Software
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18